DMAC insider trading
NasdaqCM HealthcareDiaMedica Therapeutics Inc.: insider trade history from SEC Form 4 filings.
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company also develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Company website: www.diamedica.com
DMAC insider activity at a glance
FilingIQ tracks 104 insider transactions for DMAC in filings since Dec 11, 2018. The most recent transaction is dated Aug 10, 2026.
Across the full history, 69 open-market purchases
and 1 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
How FilingIQ classifies each line, and the seven facts it shows on every open-market purchase and sale, are documented on the methodology page.
Latest DMAC Form 4 filings
Most recent disclosures. Sign up to filter by transaction code, insider role or dollar value.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for DMAC?
- FilingIQ tracks 104 Form 4 insider transactions for DMAC (DiaMedica Therapeutics Inc.), covering filings from Dec 11, 2018 onwards. 1 of those are dated within the last 90 days.
- Are DMAC insiders net buyers or net sellers?
- Across the full Form 4 history for DMAC, 69 transactions (66%) were open-market purchases and 1 (1%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does DMAC insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ links every filing to the insider's SEC CIK, marks plan trades, tax withholding, option exercises, gifts, derivatives and amendments, and shows each open-market purchase and sale with the same fixed facts. It does not rate the stock.
- What sector is DMAC in?
- DiaMedica Therapeutics Inc. (DMAC) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $357.25M.
Methodology & sources
Every DMAC insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). How lines are classified and which facts FilingIQ adds is documented on the methodology page; the people behind it are on the team page. Not investment advice; see disclaimer.